6-(3-cyanophenyl)-N-[2-[6-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]pyridine-2-carboxamide | 1093624-51-1

• 分子结构分类: 有机化合物
• 英文名称: 6-(3-cyanophenyl)-N-[2-[6-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]pyridine-2-carboxamide
• CAS: 1093624-51-1
• 化学式: C₃₃H₃₁N₇O₂S
• 分子量: 589.721
• InChiKey: JQLPANIHFMKOSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  43
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Sirtuin modulating compounds
  申请人：Bemis Jean

  公开号：US20090105246A1

  公开（公告）日：2009-04-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的调节Sirtuin的化合物及其使用方法。这些Sirtuin调节化合物可用于增加细胞寿命，并治疗/预防各种疾病和疾病，包括与衰老或压力相关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血凝障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。还提供了包含Sirtuin调节化合物与另一种治疗剂组合的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Bemis Jean

  公开号：US20110152254A1

  公开（公告）日：2011-06-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的调节Sirtuin的化合物及其使用方法。这些Sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含Sirtuin调节化合物与另一种治疗剂组合的组合物。
• Compositions and methods for modulating metabolic pathways
  申请人：NuSirt Sciences, Inc.

  公开号：US10383837B2

  公开（公告）日：2019-08-20

  Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.

  本文提供了有助于诱导脂肪酸氧化或线粒体生物生成增加、减少体重增加、诱导减肥或增加 Sirt1、Sirt3 或 AMPK 活性的组合物和方法。此类组合物可含有协同增效量的sirtuin-途径激活剂，包括但不限于白藜芦醇，与β-羟甲基丁酸（HMB）、酮异己酸（KIC）、亮氨酸或HMB、KIC和亮氨酸的组合物结合使用。
• COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS
  申请人：ZEMEL Michael

  公开号：US20130017283A1

  公开（公告）日：2013-01-17

  Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
• Compositions and Methods for Modulating Metabolic Pathways
  申请人：NuSirt Sciences, Inc.

  公开号：US20140148488A1

  公开（公告）日：2014-05-29

  Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.